Arbutus Biopharma Corp Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value
Arbutus Biopharma Corp (ABUS) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value of $0.00 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-08-12
- Arbutus Biopharma Corp share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period, weighted average grant date fair value for the quarter ending 2026-06-30 was $0.00.
- Arbutus Biopharma Corp share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period, weighted average grant date fair value for the quarter ending 2026-03-31 was $4.39, a 33.43% increase year-over-year.
- Arbutus Biopharma Corp share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period, weighted average grant date fair value for the quarter ending 2025-09-30 was $3.82.
- Arbutus Biopharma Corp share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period, weighted average grant date fair value for the quarter ending 2025-06-30 was $0.00.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month |
|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-12 | $4.39 10-Q · filed 2026-08-12 | |
| 2026-03-31 | $4.39 10-Q · filed 2026-05-13 | ||
| 2025-09-30 | $3.82 10-Q · filed 2025-11-13 | $3.58 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $0.00 10-Q · filed 2026-08-12 | $3.29 10-Q · filed 2026-08-12 | |
| 2025-03-31 | $3.29 10-Q · filed 2026-05-13 | ||
| 2024-09-30 | $0.00 10-Q · filed 2025-11-13 | $2.40 10-Q · filed 2025-11-13 | |
| 2024-06-30 | $0.00 10-Q · filed 2025-08-06 | $2.40 10-Q · filed 2025-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |